ANTH Anthera Pharmaceuticals, Inc.

0.41
+0  (2%)
Previous Close 0.40
Open 0.40
Price To book 4.76
Market Cap 20.56M
Shares 50,609,000
Volume 1,676,677
Short Ratio 2.27
Av. Daily Volume 2,383,190

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due end of 2017 or early 2018.
Sollpura - RESULT
Exocrine pancreatic insufficiency
Phase 2 primary endpoint not met following interim analysis, June 2016. Trial to continue. Noted April 10, 2017 that dosing has been completed with data due 3Q 2017.
Blisibimod
IgA nephropathy
Top-line data released December 27, 2016 - missed primary endpoint.
Sollpura (liprotamase)
Cystic fibrosis who suffer from exocrine pancreatic insufficiency
Phase 3 trial did not meet endpoints - November 10, 2016.
Blisibimod
Lupus

Latest News

  1. Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2%
  2. ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
  3. ANTH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Anthera Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of April 17, 2017
  4. Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
  5. DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Anthera Pharmaceuticals, Inc. To Contact The Firm
  6. ETFs with exposure to Anthera Pharmaceuticals, Inc. : April 7, 2017
  7. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc. -- Lead Plaintiff Deadline of April 17, 2017 -- ANTH
  8. Bill Ackman Apologizes for Valeant Investment Error
  9. Anthera's Sollpura On Par With Pancreaze Study
  10. Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura
  11. Cara Therapeutics (CARA) Shows Strength: Stock Up 5.2%
  12. Will Endo's Troubles Continue to Dent Performance in 2017?
  13. ETFs with exposure to Anthera Pharmaceuticals, Inc. : March 27, 2017
  14. Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
  15. Anthera Pharmaceuticals, Inc. :ANTH-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
  16. Enzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2%
  17. ANTH INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Anthera Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of April 17, 2017
  18. Fortress Biotech (FBIO) Catches Eye: Stock Moves Up 8.3%
  19. Implied Volatility Surging for Anthera (ANTH) Stock Options